valrubicin has been researched along with Local Neoplasm Recurrence in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Chen, W; Hu, W; Hu, X; Huang, B; Liu, N; Wang, C; Wang, S; Xing, D; Yuan, Y; Zhu, M | 1 |
| Kamat, AM; Li, R; Spiess, PE | 1 |
| Clark, PE; Eifler, JB; Scarpato, KR | 1 |
| Hale, K; Lamm, DL; McGee, WR | 1 |
| Bahnson, R; Brosman, S; Middleton, R; Steinberg, G; Wajsman, Z; Wehle, M | 1 |
| Hetherington, J; Kisbenedek, L; Newling, DW; Robinson, MR; Sundaram, SK | 1 |
3 review(s) available for valrubicin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential.
Topics: BCG Vaccine; CD8-Positive T-Lymphocytes; Humans; Mycobacterium bovis; Neoplasm Recurrence, Local; United States; Urinary Bladder Neoplasms | 2022 |
Management of noninvasive bladder cancers.
Topics: Administration, Intravesical; Antineoplastic Agents; Cystectomy; Doxorubicin; Early Detection of Cancer; Humans; Neoplasm Recurrence, Local; Risk Assessment; Risk Reduction Behavior; United States; Urinary Bladder Neoplasms | 2015 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Nurse's Role; Patient Selection; Risk Factors; Salvage Therapy; Survival Rate; Thiotepa; Treatment Failure; United States; Urinary Bladder Neoplasms | 2005 |
2 trial(s) available for valrubicin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Urinary Bladder Neoplasms | 2000 |
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2001 |
2 other study(ies) available for valrubicin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |
Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?
Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms | 2018 |